A value-per-milligram look at compounded tirzepatide: under flat pricing, higher maintenance doses deliver the lowest effective cost per mg.
Because flat-rate pricing charges the same monthly fee regardless of dose, your effective cost per milligram drops sharply as you titrate up — the opposite of dose-escalating models.
| Weekly dose | Flat monthly price | Effective cost per mg* |
|---|---|---|
| 2.5 mg | $186 | ~$18.60 / mg (per weekly mg, monthly basis) |
| 5 mg | $186 | ~$9.30 / mg |
| 7.5 mg | $186 | ~$6.20 / mg |
| 10 mg | $186 | ~$4.65 / mg |
| 12.5 mg | $186 | ~$3.72 / mg |
| 15 mg | $186 | ~$3.10 / mg |
*Illustrative: monthly price ÷ (weekly mg × ~4 weekly doses). Flat pricing means higher doses cost less per mg. For brand-name per-mg context, retail is ~$1,086/mo regardless of dose.
Maintenance doses are usually higher (10–15 mg). Under flat pricing, that's where the per-mg value is best, since you pay the same $186 whether you're on 2.5 mg or 15 mg. Dose-escalating programs invert this — your per-mg cost can stay high or rise. See maintenance cost and the price-by-dose guide.
Under flat $186/month pricing, the effective cost per mg drops as your dose rises — roughly $18.60/mg at 2.5 mg down to ~$3.10/mg at 15 mg (illustrative). Compounded tirzepatide is not FDA-approved. See NexLife pricing
With flat-rate pricing, higher doses cost less per mg because the monthly price is unchanged.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.